Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 11

1.
Full record GDS4979

Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response

Analysis of lapatinib-resistant ErbB2-positive cells treated with 0.1 or 1 uM lapatinib. Lapatinib is an EGFR/ErbB2 inhibitor used to treat ErbB2‐positive advanced or metastatic breast cancer. Results provide insight into the mechanisms underlying the development of resistance to lapatinib.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 2 cell type, 3 dose sets
Platform:
GPL6947
Series:
GSE38376
18 Samples
Download data
2.

Acquired resistance to lapatinib

(Submitter supplied) These studies are aimed at understanding gene expression chnages in a Her2 positive breast cancer cell line that has developed acquired resistance to lapatinib. Samples include SKBR3 parental and resistant (SKBR3-R) under basal conditions and in response to 0.1 and 1uM lapatinib treatment after 24 hours.
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS4979
Platform:
GPL6947
18 Samples
Download data: TXT
Series
Accession:
GSE38376
ID:
200038376
3.

BT474 and BT474-J4 microarray data

(Submitter supplied) These data provide scientific information to understand the mechanism of action of lapatinib resistance in HER2-positive patients and to test the combination of HER2-targeted agents and GSK1363089 (foretinib) in the clinic by using an acquired lapatinib-resistant cell line.
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS4083
Platform:
GPL570
18 Samples
Download data: CEL
Series
Accession:
GSE16179
ID:
200016179
4.

A comparison of DNA copy number profiling platforms using a panel of melanoma cell lines

(Submitter supplied) The accurate mapping of recurring DNA copy number aberrations (CNAs), a hallmark feature of the cancer genome, has facilitated the discovery of tumor suppressor genes and oncogenes. Microarray-based assays designed to detect these chromosomal copy number alterations on a genome-wide and high-resolution scale have emerged as a cornerstone technology in the genomic era. The diversity of commercially-available platforms prompted a systematic comparison of five copy number profiling assays for their ability to detect 2-fold copy number gain and loss (4n or 1n, respectively) as well as focal high-amplitude CNAs. more...
Organism:
Homo sapiens
Type:
Genome variation profiling by genome tiling array; Genome variation profiling by SNP array
8 related Platforms
151 Samples
Download data: CEL, TXT
Series
Accession:
GSE7822
ID:
200007822
5.
Full record GDS4083

Lapatinib-resistant HER2-positive breast tumor cells

Analysis of BT474 (lapatinib-sensitive) and BT474-J4 (acquired lapatinib-resistance) HER2+ breast cancer cells treated with lapatinib, foretinib or both. Foretinib restored lapatinib-sensitivity in BT474-J4. Results provide insight into molecular basis of acquired lapatinib-resistance in BC cells.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 4 agent, 2 cell line, 2 genotype/variation sets
Platform:
GPL570
Series:
GSE16179
18 Samples
Download data: CEL
DataSet
Accession:
GDS4083
ID:
4083
6.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

(Submitter supplied) HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kinase inhibitor (TKI) lapatinib, show antitumor activity in a limited proportion of patients, indicating that HER2 can be still exploited as a target after trastuzumab failure. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL4133
2 Samples
Download data: TXT
Series
Accession:
GSE17630
ID:
200017630
7.

The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Other; Expression profiling by high throughput sequencing
Platform:
GPL21290
24 Samples
Download data
Series
Accession:
GSE144380
ID:
200144380
8.

The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer [RNA-seq]

(Submitter supplied) Recent studies suggested that crosstalk between ERα and EGFR/HER2 pathways plays a critical role in mediating endocrine therapy resistance. Several targeting EGFR/HER2 signaling inhibitors including FDA-approved lapatinib and gefitinib as well as a novel dual tyrosine kinase inhibitor (TKI) sapitnib showed greater inhibitory efficacies. However, how a 3D chromatin landscape of the response to the inhibition to EGFR/HER2 pathway remains to be elucidated. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL21290
18 Samples
Download data: TXT, XLSX
Series
Accession:
GSE144378
ID:
200144378
9.

The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer [HiC]

(Submitter supplied) Recent studies suggested that crosstalk between ERα and EGFR/HER2 pathways plays a critical role in mediating endocrine therapy resistance. Several targeting EGFR/HER2 signaling inhibitors including FDA-approved lapatinib and gefitinib as well as a novel dual tyrosine kinase inhibitor (TKI) sapitnib showed greater inhibitory efficacies. However, how a 3D chromatin landscape of the response to the inhibition to EGFR/HER2 pathway remains to be elucidated. more...
Organism:
Homo sapiens
Type:
Other
Platform:
GPL21290
6 Samples
Download data: XLSX
10.

Genome-wide chromatin interactions identify characteristic promoter-distal loops

(Submitter supplied) We developed a novel computational model, HiSIF (Hi-C Significant Interacting Fragments), which uses a Poisson Mixture Model (PMM) with a power-law decay background. We compared its performance to some existing programs with publicly available Hi-C data, and then applied it to in situ Hi-C data in breast cancer sensitive and resistant cells.
Organism:
Homo sapiens
Type:
Other
Platform:
GPL21290
4 Samples
Download data: TXT
11.

Expression data from human cancer cells treated with UPR modulators under ER stress conditions

(Submitter supplied) The unfolded protein response (UPR) is a cellular defense mechanism against glucose deprivation, a cell condition that occurs in solid tumors. A key feature of the UPR is the activation of the transcription program that allows the cell to cope with endoplasmic reticulum (ER) stress. We used micoarrays to show that the UPR transcription program is disrupted by the antitumor macrocyclic compound versipelostatin (VST) and antidiabetic biguanides metformin, buformin and phenformin, depending on cellular glucose availability. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
42 Samples
Download data: CEL
Series
Accession:
GSE13548
ID:
200013548
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=2|blobid=MCID_616d4c0a45cdce07898de8c3|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center